Table 1.
Clinical Feature | Median [Range] or No. (%) | P | |
---|---|---|---|
No ESA, n = 391 | ESA, n = 217 | ||
Age, y | 49 [15–81] | 57 [17–84] | <.0001 |
Male sex | 258 (66) | 94 (43) | <.0001 |
Stage | .92 | ||
ECP | 198 (51) | 109 (50) | |
LCP | 193 (49) | 108 (50) | |
Spleen size, cm from left costal margin | 0 [0–20] | 0 [0–25] | .32 |
WBC, ×109/L | 14.5 [1.6–283] | 18 [1.8–239] | .14 |
Hb, g/dL | 12.9 [7.9–16.9] | 11.7 [6.2–14.6] | <.0001 |
Platelets, ×109/L | 288 [58–1476] | 334 [82–1324] | .09 |
PB blasts | 0 [0–12] | 0 [0–12] | .08 |
BM blasts | 1 [0–14] | 1 [0–14] | .10 |
Sokal risk score | <.0001 | ||
Low | 299 (76) | 124 (57) | |
Intermediate | 77 (20) | 75 (35) | |
High | 15 (4) | 18 (8) | |
Previous IFN-α | 194 (50) | 108 (50) | .97 |
Ph1+ at start of imatinib >90% | 320 (82) | 189 (88) | .10 |
Time from diagnosis to imatinib, mo | 8 [0–218] | 6.5 [0–194] | .61 |
High dose imatinib, % | 155 (40) | 94 (43) | .37 |
ESA indicates erythropoietic-stimulating agent; ECP, early chronic phase; LCP, late chronic phase; WBC, white blood cell count; Hb, hemoglobin; PB, peripheral blood; BM, bone marrow; IFN, interferon; Ph1+, Philadelphia chromosome positive.